Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015301 · ClinicalTrials.gov registry record · Phase 4

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

A Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 4
Development phase
1
Study location

NCT00015301 is a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015301, a Phase 4 study of Substance-Related Disorders and Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 4
Development phase
1
Study location

Study Summary

The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Interventions

  • DRUG Methylphenidate

Study Locations (1)

New York

  • New York MDRU - New York

Trial Details

FieldValue
Start Date 2003-12
Est. Completion 2005-08
Phase Phase 4

What the Registry Record Tells You About NCT00015301

The ClinicalTrials.gov registry entry for NCT00015301 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.

NCT00015301 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00015301 about?

NCT00015301 is a clinical study titled "Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11". The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

What is the current status of trial NCT00015301?

This trial is currently completed. It is a Phase 4 study. The study started on 2003-12. Estimated completion is 2005-08.

What conditions does trial NCT00015301 study?

This clinical trial studies the following conditions: Substance-Related Disorders, Cocaine-Related Disorders.

What interventions are being tested in trial NCT00015301?

The interventions under investigation include: Methylphenidate (DRUG).

Who is sponsoring clinical trial NCT00015301?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00015301 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.